Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30823293 | 1.00 | BCHE (0.36) | BCHEACHEGAAKMT2ANPY5R | |
| SCHEMBL21325823 | 0.81 | BCHE (0.40) | BCHEACHE | |
| SCHEMBL21178416 | 0.81 | KDM4E (0.32) | GAAKMT2A | |
| SCHEMBL30823303 | 0.81 | KDM4E (0.32) | GAAKMT2A | |
| SCHEMBL13633973 | 0.72 | MKNK1 (0.35) | BCHEACHE | |
| SCHEMBL12501306 | 0.72 | PARP1 (0.50) | BCHEACHEKMT2A | |
| SCHEMBL247638 | 0.72 | BCHE (0.34) | BCHEACHE | |
| SCHEMBL247885 | 0.72 | HTR5A (0.36) | BCHEACHEGAA | |
| SCHEMBL437139 | 0.69 | NCF1 (0.42) | BCHEACHEGAAKMT2A | |
| SCHEMBL247411 | 0.68 | BCHE (0.34) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | BCHE 3273/4885ACHE 4436/4885GAA 291/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | BCHE 3273/4885ACHE 4436/4885GAA 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.